Genmab — August 2018
-
Lego: The DMC determined that there was no observed benefit within the combination treatment arm, daratumumab plus atezolizumab, over atezolizumab monotherapy, and recommended termination of the study. In addition to the lack of benefit, the DMC noted a numerical increase in mortality-related events in the combination arm.
-
New Phase 3 Ofa/MS https://clinicaltrials.gov/ct2/show/NCT03650114?term=NCT03650114&rank=1
-
Genentech indgår lukrativ kræftalliance med tidligere Novo Nordisk-satsning
Roche-selskabet Genentech skal udvikle immunterapier mod kræft sammen med det tyske biotekselskab Affimed, som tidligere var en del af Novo Nordisks venture-satsning og som den danske koncern fortsat ejer aktier i. Aftalen kan indbringe det tyske selskab mere end 30 mia. kr.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind